Since its creation in 2012, ECELLFRANCE has been involved in over 20 national and European clinical trial programs in cell therapy using adult mesenchymal stem cells (MSC).
The diseases targeted include : Osteoarthritis, Multiple sclerosis, Pseudoarthrosis, Femoral head necrosis, Stroke, Myocardial infarction, Pelvic radiation disease, Scleroderma, Cardiac failure, Cartilage injuries, Degenerative disk disease, Septic shock, Recessive Dystrophic Epidermolysis Bullosa (RDEB), Rheumatoid arthritis, Critical limb ischemia, Venous Leg Ulcers, Non-union femoral head osteonecrosis, and Fistula Crohn disease.
The MSC are produced by our ATMP production platforms (4 EFS + 1 CTSA production platforms). The cells are issued from bone marrow or adipose tissue, the transplants can be autologous or allogeneic, cells are administered either locally or systemically and they are associated with a biomaterial in 25% of the projects.
Some of the projects are carried by external project carriers (academics or industrials) who have requested support for their pre-clinical and/or clinical programs from ECELLFRANCE.
If you wish to request support for your cell-based therapy project you may apply by filling the application form.